to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults with Relapsed or Refractory Primary Light-Chain Amyloidosis
Voluntary provision of written informed consent and ability to comply with protocol requirements.
Age ≥18 years, any gender.
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.
Confirmed diagnosis of primary light-chain (AL) amyloidosis.
Current or prior diagnosis of multiple myeloma.
Received anti-AL amyloidosis therapy within protocol-specified timeframe prior to first dose.
Clinically significant cardiovascular or cerebrovascular disease.
Any active or uncontrolled infection meeting protocol-defined criteria.